Inverse relationship between patient peripheral blood CD34+ cell counts and collection efficiency for CD34+ cellsin two automated leukapheresis systems

Heuft, Hans‐Gert; Dubiel, Mark; Rick, Oliver; Kingreen, D.; Serke, Stefan; Schwella, N.

doi:10.1046/j.1537-2995.2001.41081008.x

Cited by 32 publications

(54 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, the CE of 46% seen here is in keeping with that reported by others 4,6,7 and by us in a smaller number of patients. 2,3 Age, ideal body weight, and underlying disease did not correlate with CE.…”

Section: Tablesupporting

confidence: 93%

Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?

Gidron

Verma

Doyle

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:A total of 415 leukaphereses in 201 patients stimulated with growth factor (GF; n ¼ 119) or chemotherapy-GF (n ¼ 296) were studied to determine CD34 þ cell collection efficiency (CE). The pre-apheresis leukocyte count was 1-93 Â 10 9 /l (median 20), and peripheral blood CD34 count (PBCD34) was 1-1104/ll (median 19). The total number of CD34 þ cells collected was 4-6531 Â 10 6 (median 151); corresponding to 0.1-111.4 Â 10 6 (median 2.3) per kg. There was strong correlation between PBCD34 and the number of CD34 þ cells collected (r ¼ 0.9; Po0.0001). CE was 7-145% (median 46). On multiple regression analysis, a higher leukocyte count (Po0.0001) was the most important predictor of lower CE. CE with leukocytes o20 was 7-145% (median 53%) compared to 10-132% (median 40%) with leukocyte X20 (Po0.0001). In all, 61% of the apheresis procedures performed after chemotherapy-GF occurred when leukocytes were o20 compared to 21% of those performed after GF alone (Po0.0001). We conclude that mobilizing patients with the combination of chemotherapy and GF rather than GF alone leads to leukapheresis being performed when the leukocyte count is low -in a range that results in optimum CD34 þ cell CE. Autologous stem cells should be mobilized with chemotherapy-GF rather than GF alone whenever possible. Bone Marrow Transplantation (2005) 35, 243-246.

show abstract

Section: Tablesupporting

confidence: 93%

Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?

Gidron

Verma

Doyle

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…11 Maximizing CE is essential to collect as many CD34 ϩ cells as posible over a given number of apheresis procedures or to reach a given target with fewer apheresis procedures. In either case, the use of a machine with a higher CD34 ϩ CE is more cost-efficient.…”

Section: Discussionmentioning

confidence: 99%

“…7 A number of studies have compared CEs of different cell separators retrospectively and prospectively. [8][9][10][11][12][13] The practice at our institution has been to use CS 3000 Plus cell separators almost exclusively for leukapheresis until recently when Cobe Spectra separators began to be employed regularly. This retrospective analysis was undertaken to compare the CEs of the two machines to see if there was a difference between them -and to determine the best way of employing different cell separators under normal clinical circumstances.…”

mentioning

confidence: 99%

Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells

Mehta

Singhal

Gordon

et al. 2002

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:One hundred and seventy-seven stem cell apheresis procedures performed on 91 patients using the Fenwal CS 3000 Plus cell separator and 61 procedures performed on 37 patients using the Cobe Spectra cell separator were studied to compare the CD34 ؉ cell collection efficiencies (CE; the proportion of the total CD34 ؉ cell content in the blood volumes processed that is harvested) of the two machines. The absolute peripheral blood CD34؉ cell count was comparable for the two groups (P ‫؍‬ 0.27). A strong correlation was seen between the blood CD34 ؉ cell count and the total number of CD34 ؉ cells collected for the Spectra (r 2 ‫؍‬ 0.59; P Ͻ 10 ؊6) and for the CS 3000 Plus (r 2 ‫؍‬ 0.60; P Ͻ 10 ؊6 ). No significant correlation emerged between the peripheral blood CD34؉ cell count and the CE of either machine. The total number of CD34 ؉ cells collected per procedure was comparable (P ‫؍‬ 0.51): median 113 ؋ 10 6 for CS 3000 Plus and median 218 ؋ 10 6 for Spectra. CE was significantly higher with the Spectra (median 45.7%, range 9.8-98.6%) than the CS 3000 Plus (median 30.3%, range 1.7-89.3%; P Ͻ 0.00001). We conclude that the CD34 ؉ cell CE of the Spectra is superior to that of the CS 3000 Plus. Therefore, under the usual clinical conditions, Cobe Spectra should be used preferentially for peripheral blood progentor cell collection to maximize the number of hematopoietic stem cells collected.

show abstract

“…The most commonly used system is the COBE Spectra apheresis system (Terumo BCT, Tokyo, Japan), which requires intermittent optical/manual input from the operator, making it labor-intensive and prone to user-dependent variability [34]. The quality of the cells collected with apheresis systems such as COBE has been reported to depend on the operator and stable blood flow [56].…”

mentioning

confidence: 99%

Comparison of Two Apheresis Systems of COBE and Optia for Autologous Peripheral Blood Stem Cell Collection

et al. 2017

View full text Add to dashboard Cite

Peripheral blood stem cell (PBSC) transplantation following myeloablative therapy is a mainstay of treatment for various types of malignancies. This study aimed to evaluate the differences between the Optia MNC and COBE Spectra MNC systems (Terumo BCT, Japan) according to apheresis procedures and the parameters of apheresis, products, and collection. The clinical data of 74 patients who underwent autologous PBSC collection from July 2012 to July 2015 were reviewed retrospectively. The patients comprised 48 (65%) men and 26 (35%) women with a median age of 56 yr (range, 23–66 yr). Of 216 procedures, 111 (51%) and 105 (49%) were processed by using COBE and Optia MNC, respectively. PBSC collection rates, throughput, numbers of stem cells retrieved, collection efficacy, and platelet loss were compared. There were no significant differences in the median CD34+ cell counts of collected products (0.61×108 vs 0.94×108), CD34 collection efficiency (43.5% vs 42.1%), and loss of platelets (40.1% vs 44.7%). The Spectra Optia MNC apheresis system was comparable to the COBE Spectra system in collecting autologous CD34+ hematopoietic stem cells and retention of platelets.

show abstract

Inverse relationship between patient peripheral blood CD34+ cell counts and collection efficiency for CD34+ cellsin two automated leukapheresis systems

Cited by 32 publications

References 31 publications

Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?

Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?

Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells

Comparison of Two Apheresis Systems of COBE and Optia for Autologous Peripheral Blood Stem Cell Collection

Contact Info

Product

Resources

About